Deregulation of Tau protein expression and/or metabolism in the CNS is closely linked to tauopathies, which comprise several disorders mainly characterized by the accumulation of aggregated and hyperphosphorylated Tau protein in the brains of patients, including AD, progressive supranuclear palsy (PSP) corticobasal degeneration (CBD), or Pick’s disease (PiD) [6–8]. The gene discussed is MAPT; the disease is red-green color blindness.